Gilead Sciences and Glympse Bio, a developer of non-invasive technology for disease activity, have entered into a strategic collaboration for nonalcoholic steatohepatitis (NASH) clinical development.

Glympse Bio’s proprietary synthetic biomarkers, bioengineered to identify stage and progression of disease as well as early detection of treatment response, will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical program.

Glympse Bio’s proprietary technology, Glympse Inside, combines synthetic biomarkers with machine-learning approaches to identify the stage and monitor progression of complex diseases such as cancer, fibrosis, inflammation, and infections, in real time.

Financial terms of the agreement were not disclosed.

Source: Gilead Sciences